Fulgent Genetics, Inc. (FLGT)
Fulgent Genetics, Inc. (FLGT) from its SEC filings: 2025 revenue $322.7 million (+14% vs the year before), net margin -19%, free cash flow -$124.2 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Services-Medical Laboratories |
| Revenue (2025) | $322.7 million |
| Revenue growth | +14% |
| Net income | -$60.5 million |
| Net margin | -18.8% |
| Free cash flow | -$124.2 million |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +4% |
| Cash | $26.3 million |
| Share count, 1 year | -10% |
| Fundamentals check | Mixed fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-24. Education only, not financial advice.